The Living Heart Project, launched in 2014 by Dassault Systèmes, has developed physics-based virtual twins of the human heart and other organs to guide surgical planning and clinical decisions. Built on industrial-grade simulation software and personalized using patient MRI, CT, and echocardiogram data, the technology has now guided nearly 2,000 procedures at Boston Children's Hospital. In 2024, the project completed an FDA-sponsored in silico clinical trial initiative, establishing the first FDA-led guidelines for virtual patient trials. Generative AI now enables rapid creation of large virtual patient cohorts, reducing the time and cost of drug and device trials. The project has expanded beyond the heart to model lungs, liver, brain, eyes, and gut, moving toward a unified modular virtual human platform. Future directions include real-time updates from wearables and patient-facing tools for understanding treatment outcomes.